Oncimmune signs agreement with Augmenta Bioworks to discover therapeutic antibodies
LONDON: Oncimmune Holdings plc has signed a new master service agreement with Augmenta Bioworks Inc. to profile patient plasma samples and characterise therapeutic candidates discovered through Augmenta’s SingleCyte and DeepGrid discovery platforms. Augmenta is a California-based biotech company which works…